BriaCell Therapeutics Corp. (BCTX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
Bellevue Centre
West Vancouver, BC V7T 2X1
Canada
Phone
604 921 1810
Website
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
March 14, 2012
| Name | Title | Pay | Year Born |
| William V. Williams | Chief Executive Officer, President & Director | 711,724 | 1955 |
| Charles Louis Wiseman FACP | Founder, Principal Research Advisor & Member of Scientific Advisory Board | 241,138 | 1947 |
| Miguel A. Lopez-Lago | Chief Scientific Officer | 447,547 | 1970 |
| Giuseppe Del Priore | Chief Medical Officer | 493,048 | 1962 |
| Gadi Levin | Chief Financial Officer & Corporate Secretary | 535,361 | 1973 |
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.